Once the ALKAL binds with ALK and dimerizes with another ALK-ALKAL complex, this activated conformation also initiates a conformational change of the intracellular kinase domain of ALK. This causes an autophosphorylation of several tyrosine residues of this domain, activating a signaling cascade with its kinase activity.
Once the ALKAL binds with ALK and dimerizes with another ALK-ALKAL complex, this activated conformation also initiates a conformational change of the intracellular kinase domain of ALK. This causes an autophosphorylation of several tyrosine residues of this domain, activating a signaling cascade with its kinase activity.
== Disease ==
== Disease ==
There are many <scene name='90/904317/Premutationresidues/1'>residues that could be mutated</scene> that would cause constitutive receptor activation, enhancement between the interaction of receptors or stabilization of active receptors are known to relate to oncogenic potentials (Figure 4). The <scene name='90/904317/His694/2'>His694</scene> that is mutated to an arginine is known to be a gain-of-function in lung adenocarcinoma which can lead to constitutive activation of ALK. The <scene name='90/904317/Phe856/1'>Phe856</scene> that is mutated to the a serine may cause a gain-of-function mutation that is linked to acute myeloid leukemia. When the <scene name='90/904317/Arg753/1'>Arg753</scene> is mutated to a glutamate it is commonly identified in histiocytic neoplasms. The <scene name='90/904317/Gly747/1'>Gly747</scene> changing to arginine could cause possible oncogenic potentials which are not specified yet. The F856S and R753Q mutations are known to increase cytokine-dependent cell proliferation in certain cells. <ref>DOI:10.1038/s41586-021-03959-5</ref>
There are many <scene name='90/904317/Premutationresidues/1'>residues that could be mutated</scene> that would cause constitutive receptor activation, enhancement between the interaction of receptors or stabilization of active receptors are known to relate to oncogenic potentials (Figure 4). The <scene name='90/904317/His694/2'>His694</scene> that is mutated to arginine is known to be a gain-of-function in lung adenocarcinoma which can lead to constitutive activation of ALK (Fig. 4a). The <scene name='90/904317/Gly747/1'>Gly747</scene> changing to arginine could cause possible oncogenic potentials which are not specified yet (Fig. 4b). The F856S and R753Q mutations are known to increase cytokine-dependent cell proliferation in certain cells. <ref>DOI:10.1038/s41586-021-03959-5</ref>
[[Image:Screen Shot 2022-04-13 at 5.30.04 PM.png|800 px|left|thumb|Figure 4: Mutated residues on ALK that contribute to stabilization of the active state of ALK, leading to many types of cancers. From left to right: F856S, G747R, H694R, R753Q [https://www.rcsb.org/structure/7N00 PDB: 7N00]]]
[[Image:Screen Shot 2022-04-13 at 5.30.04 PM.png|800 px|left|thumb|Figure 4: Mutated residues on ALK that contribute to stabilization of the active state of ALK, leading to many types of cancers. From left to right: F856S, G747R, H694R, R753Q [https://www.rcsb.org/structure/7N00 PDB: 7N00]]]
The anaplastic lymphoma kinase (ALK) was first discovered in 1994 as a tyrosine kinase in anaplastic large-cell lymphoma (ALCL) cells.[1] The specific type of tyrosine kinase ALK is classified as is a receptor tyrosine kinase (RTK) and like other RTKs, it's an integral protein with extracellular and intracellular domains and is involved in transmembrane signaling and communication within the cell. ALK is commonly expressed in the development of the nervous system. Anaplastic lymphoma kinase receptor (ALKr) is the extracellular portion of the RTK that includes a binding surface for a ligand to bind. When the ALK activating ligand (ALKAL) binds to ALKr, this causes a conformational change of ALK, allowing two ALK-ALKAL complexes to interact with each other, which will then allow intracellular kinase domain of ALK to phosphorylate a tyrosine residue on a downstream enzyme, which will activate this enzyme and activate a signaling cascade. Abnormal forms of ALK are closely related to the formation of several cancers. [2]
Structure & Function
Domains
Figure 1: Anaplastic Lymphoma Kinase and its domains.
The region from NTR (N-terminal region) to the MAM is the Heparin Binding Domain. The TNFL through the PXL (polyglycine extension loop) are the extracellular domains and the EGF is the domain that binds to the TMH (transmembrane region) region in the membrane. The kinase domain is the intracellular portion of the ALK and the structure has not been discovered. The only structures that have been fully discovered are in color (Figure 1). The growth factor-like domain (EGF) connects the extracellular domains to the transmembrane domain (cyan). The tumor necrosis factor-like domain (TNFL) has a beta-sandwich structure that provides important residues that act as the binding surface for the ligand (orange). The glycine-rich domain (GlyR) contains 14 rare polyglycine helices that are hydrogen-bound to each other (green). The extracellular portion of ALK has an inactive state monomer, and upon ligand binding, ALK transitions to an active dimerized state. The monomer has many different domains (Figure 1). The hexagonal orientation of these rare helices create a rigid structure that is important for ALK function. The GlyR domain functions as a scaffold to anchor the ligand-binding site on the TNF-like domain and the overall dimerization of the three-helix bundle. The polyglycine extension loop (PXL) connects two of these polyglycine helices (pink).
The domains that aren't shown in Figure 2 but are shown in the domain map (Figure 1) also make up the monomer. The heparin binding domains (HBDs), are at the N-terminal end of the monomer. Heparin has been found to be a possible activating ligand of ALK.[3] The transmembrane domain (TMH) contains the residues of ALK that are located within the membrane. The kinase domain is the intracellular portion of ALK that contains the Tyr residues which are auto-phosphorylated when ALK is activated, initiating a signaling cascade. [4]
Figure 3: ALK-ALKAL complex, showing the conformation change of ALK from the binding of ALKAL. PDB: 7N00
Membrane Guidance of ALKAL to ALK
The first step to the activation of ALK is to bind the ALK activating ligand (ALKAL) to ALKr. ALKAL is a triple alpha-helix polypeptide structure that signals for a conformational change of ALK. What allows ALKAL to interact with ALKr is the cell membrane. The negatively charged phosphate groups on the cell membrane interact with a highly conserved positively charged helix on ALKAL that faces the membrane. These residues that interact with the cell membrane(7MZZ) guide ALKAL to ALKr and correctly positions ALKAL for its binding surface to face ALKr's binding surface, which allows for a more favorable interaction.
Conformational Change
ALKAL binds to ALKr at the TNFL domain, which has important negatively charged residues that form ionic bonds with positively charged residues on ALKAL. These bonds initiate the conformational change, as these residues can only come into close proximity with each other if the conformational change occurs. The PXL and GlyR domains hinge forward when the change is initiated[5] (Figure 2). Glu978, Glu974, Glu859, and Tyr966 are the residues of ALKr that form these bonds with Arg123, Arg133, Arg136, Arg140, and Arg117 of ALKAL. Once the ALK-ALKAL complex is formed, the dimerization of two ALK-ALKAL complexes occurs. The main driving force of the interaction between two ALK-ALKAL complexes that dimerize are hydrophobic interactions of the PXL loop of one ALKr with the other complex's ALKAL and TNFL domain of ALKr. This dimer of two ALK-ALKAL complexes is the active form of ALK, and it is now able to perform its main function of phosphorylation.
Role of Activated ALK
Once the ALKAL binds with ALK and dimerizes with another ALK-ALKAL complex, this activated conformation also initiates a conformational change of the intracellular kinase domain of ALK. This causes an autophosphorylation of several tyrosine residues of this domain, activating a signaling cascade with its kinase activity.
Disease
There are many residues that could be mutated that would cause constitutive receptor activation, enhancement between the interaction of receptors or stabilization of active receptors are known to relate to oncogenic potentials (Figure 4). The His694 that is mutated to arginine is known to be a gain-of-function in lung adenocarcinoma which can lead to constitutive activation of ALK (Fig. 4a). The Gly747 changing to arginine could cause possible oncogenic potentials which are not specified yet (Fig. 4b). The F856S and R753Q mutations are known to increase cytokine-dependent cell proliferation in certain cells. [6]
Figure 4: Mutated residues on ALK that contribute to stabilization of the active state of ALK, leading to many types of cancers. From left to right: F856S, G747R, H694R, R753Q PDB: 7N00
↑Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. Int J Mol Sci. 2018 Nov 2;19(11). pii: ijms19113448. doi: 10.3390/ijms19113448. PMID:30400214 doi:https://dx.doi.org/10.3390/ijms19113448
↑Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. Int J Mol Sci. 2018 Nov 2;19(11). pii: ijms19113448. doi: 10.3390/ijms19113448. PMID:30400214 doi:https://dx.doi.org/10.3390/ijms19113448
↑Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916. PMID:25605972 doi:https://dx.doi.org/10.1126/scisignal.2005916
↑Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE. Structural basis for ligand reception by anaplastic lymphoma kinase. Nature. 2021 Dec;600(7887):148-152. doi: 10.1038/s41586-021-04141-7. Epub 2021, Nov 24. PMID:34819665 doi:https://dx.doi.org/10.1038/s41586-021-04141-7
↑Reshetnyak AV, Rossi P, Myasnikov AG, Sowaileh M, Mohanty J, Nourse A, Miller DJ, Lax I, Schlessinger J, Kalodimos CG. Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature. 2021 Dec;600(7887):153-157. doi: 10.1038/s41586-021-04140-8. Epub 2021, Nov 24. PMID:34819673 doi:https://dx.doi.org/10.1038/s41586-021-04140-8
↑De Munck S, Provost M, Kurikawa M, Omori I, Mukohyama J, Felix J, Bloch Y, Abdel-Wahab O, Bazan JF, Yoshimi A, Savvides SN. Structural basis of cytokine-mediated activation of ALK family receptors. Nature. 2021 Oct 13. pii: 10.1038/s41586-021-03959-5. doi:, 10.1038/s41586-021-03959-5. PMID:34646012 doi:https://dx.doi.org/10.1038/s41586-021-03959-5